As a Co-primary Target, Should Remnant Cholesterol Replace Non-HDL-C?

As a Co-primary Target, Should Remnant Cholesterol Replace Non-HDL-C?

  • What to measure?
    • Lab results: TGs, remnant cholesterol, non-HDL-C.
  • What you estimate?
    • TGs in remnants + LDL + HDL; remnant cholesterol, cholesterol in remnants + LDL + Lp(a).
  • Remnant (VLDL) cholesterol explains residual ASCVD risk.
  • Treatment increasing remnant-C and TGs:
    • Eat less
    • Exercise more
    • Treat diabetes
    • Reduce alcohol
    • High-intensity statin + fibrate + icosapent ethyl (EPA)
    • Fish oils.

user
Dr. Barge Prof. G Nordestgaard

Dr. Barge Prof. G Nordestgaard is a Professor Nordestgaard has for more than 30 years continued his interest in the pathogenesis. In 1985, he graduated as a medical doctor from University of Copenhagen. Scientific education included 2 years at Cornell University in Ithaca, New York, and 2 years St. Thomas's Hospital in London, UK. In 1990 he was Awarded Doctor of Medical Sciences by University of Copenhagen and in 2016. Honorary Doctorate by University of Buenos Aires, Argentina. He was an Executive Committee member of the European Atherosclerosis Society and in 1999-02 an Executive Scientific Committee member of the European Society of Cardiology.

Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks